Physician profile
Jason Rogart
NPI 1477648426
$22,383.58
in general payments reported to CMS, 2019-2025
8 companies · $3,558 in 2025
The $3,558 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $4,413 · 2021: $3,269 · 2022: $5,964 · 2023: $4,694 · 2024: $315 · 2025: $3,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,000 · Food and Beverage: $1,401 · Travel and Lodging: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,000.00 |
| Food and Beverage | $1,401.28 |
| Travel and Lodging | $165.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21,778.54 | 2019-2025 | General - Therapies, Resolution 360 Clip, Axios |
| Abbvie INC. | $217.29 | 2025 | |
| Medtronic, INC. | $182.71 | 2021-2023 | Gi Genius |
| Olympus America INC. | $101.65 | 2023 | Evis Exera III Duodenovideoscope |
| Cook Medical LLC | $35.38 | 2019 | |
| Janssen Biotech, INC. | $29.22 | 2022 | |
| Daiichi Sankyo INC. | $20.04 | 2022 | |
| Genzyme Corporation | $18.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Rogart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.